ライフサイエンスコーパス: myotonic dystrophy

1 ed and studied with respect to their role in myotonic dystrophy.

2 lular localization is a central component of myotonic dystrophy.

3 ead to muscle degeneration disorders such as myotonic dystrophy.

4 des to treat Duchenne muscular dystrophy and myotonic dystrophy.

5 skeletal actin, long repeat) mouse model of myotonic dystrophy.

6 ion disorders such as Huntington disease and myotonic dystrophy.

7 onduction delay, two predominant features of myotonic dystrophy.

8 gene causes the autosomal dominant disorder myotonic dystrophy.

9 bias seen in expanded CTG triplet repeats in myotonic dystrophy.

10 causes symptoms in the neuromuscular disease myotonic dystrophy.

11 isorders, including Huntington's disease and myotonic dystrophy.

12 bset of the cardiac dysfunctions observed in myotonic dystrophy.

13 ical diseases such as Huntington disease and myotonic dystrophy.

14 a potential drug target for the treatment of myotonic dystrophy.

15 sting a toxic RNA pathogenesis, as occurs in myotonic dystrophy.

16 e diseases, including Huntington disease and myotonic dystrophy.

17 ssues, including heart failure, diabetes, or myotonic dystrophy.

18 uscle weakness and wasting characteristic of myotonic dystrophy.

19 disease severity and therapeutic response in myotonic dystrophy.

20 facioscapulohumeral muscular dystrophy, and myotonic dystrophy.

21 hogenic feature of the neuromuscular disease myotonic dystrophy.

22 hat are specific to skeletal muscle, and the myotonic dystrophies.

23 c syndromes, with particular emphasis on the myotonic dystrophies.

24 Myotonic dystrophy 1 (DM1) is a multi-system disorder ch

25 Myotonic dystrophy 1 (DM1) is a multisystemic disease ca

26 In myotonic dystrophy 1 (DM1), aggregation of the mutant DM

27 f skeletal muscle pathology in patients with Myotonic Dystrophy 1 (DM1).

28 Myotonic dystrophy 2 (DM2) is a multisystem skeletal mus

29 Myotonic dystrophy 2 (DM2) is an autosomal dominant, mul

30 MPK at the DM1 locus on chromosome 19 causes myotonic dystrophy, a dominantly inherited disease chara

31 es of repeat instability and pathogenesis in myotonic dystrophy, a neurological disorder caused by an

32 Myotonic dystrophy, a progressive autosomal dominant dis

33 disease process raises the possibility that myotonic dystrophy, among genetic disorders, may be unus

34 known RNA-mediated disorders, including the myotonic dystrophies and fragile X tremor ataxia syndrom

35 tor protein that plays a pivotal role in the Myotonic Dystrophies and Huntington's Disease, and sever

36 the results with those of four patients with myotonic dystrophy and 12 healthy individuals.

37 t sequences 5'-(CTG)n and 5'-(CGG)n leads to myotonic dystrophy and fragile X syndrome, respectively.

38 ely short triplet-repeat expansions found in myotonic dystrophy and Friedreich's ataxia confer varieg

39 ween the pathogenic RNA repeat expansions of myotonic dystrophy and MBNL1.

40 Using a cell culture model of myotonic dystrophy and myotonic dystrophy patient tissue

41 ls are key players in both the human disease myotonic dystrophy and the regulation of alternative spl

42 ts in Friedreich's ataxia, (CTG)n repeats in myotonic dystrophy, and (CGG)n repeats in fragile X synd

43 , and 830 repeats of (CTG)n, which codes for myotonic dystrophy, and 130 and 600 repeats of (CGG)n, w

44 sity in humans as may occur in, for example, myotonic dystrophy, and possibly, the metabolically obes

45 ncy contributes to the cataract phenotype in myotonic dystrophy, and that myotonic dystrophy represen

46 rdiac electrophysiological disease; one with myotonic dystrophy; and one with hypertrophic cardiomyop

47 Myotonic dystrophies are the most common, comprising 28.

48 nic mouse model to show that derangements of myotonic dystrophy are reversed by a morpholino antisens

49 leblind-like 1 (MBNL1), a gene implicated in myotonic dystrophy, as a robust suppressor of multiorgan

50 SIX5 (previously known as myotonic dystrophy associated homeodomain protein - DMAH

51 This process is dysregulated in myotonic dystrophy because MBNL proteins are sequestered

52 for a therapeutic strategy for treatment of myotonic dystrophy by ablating or silencing expression o

53 sis might have a clinically relevant role in myotonic dystrophy cardiac conduction defects and pathol

54 e splicing and polyadenylation in congenital myotonic dystrophy (CDM).

55 r generation of massive instabilities of the myotonic dystrophy CTG.CAG sequences.

56 (TTC) repeats from the fragile X (CGG).CCG), myotonic dystrophy (CTG).(CAG) and the Huntington (CAG).

57 The myotonic dystrophies (DM) are human diseases in which th

58 sion of a CTG repeat at the DM1 locus causes myotonic dystrophy (DM) by altering the expression of th

59 Myotonic dystrophy (DM) is a genetic disorder caused by

60 Myotonic dystrophy (DM) is a multi-system neuromuscular

61 Myotonic dystrophy (DM) is a multisystemic disease cause

62 Myotonic dystrophy (DM) is a multisystemic disorder caus

63 Myotonic dystrophy (DM) is an autosomal dominant disorde

64 utant myotonin protein kinase (DMPK) mRNA in myotonic dystrophy (DM) is associated with alterations i

65 Myotonic dystrophy (DM) is caused by a CTG expansion in

66 Myotonic dystrophy (DM) is caused by a triplet repeat ex

67 Myotonic dystrophy (DM) is caused by either an untransla

68 The neuromuscular disease myotonic dystrophy (DM) is caused by microsatellite repe

69 Myotonic dystrophy (DM) is caused by the expression of m

70 Myotonic dystrophy (DM) is caused by two similar noncodi

71 ansion in the 3' UTR of the DMPK gene causes myotonic dystrophy (DM) is unknown.

72 a topic of intense study due to its role in myotonic dystrophy (DM) pathogenesis.

73 rentiation of skeletal muscle is affected in myotonic dystrophy (DM) patients.

74 The RNA-mediated disease model for myotonic dystrophy (DM) proposes that microsatellite C(C

75 Myotonic dystrophy (DM) type 1 is associated with an exp

76 (MBNL) protein family has been implicated in myotonic dystrophy (DM), a specific function for these p

77 In myotonic dystrophy (DM), expression of RNA containing ex

78 t roles in muscle and eye development and in myotonic dystrophy (DM), in which expanded CUG or CCUG r

79 Myotonic dystrophy (DM), the most common form of muscula

80 Myotonic dystrophy (DM), the most common form of muscula

81 Myotonic dystrophy (DM), the most common form of muscula

82 Myotonic dystrophy (DM), the most common form of muscula

83 proposed first for the neuromuscular disease myotonic dystrophy (DM), which is associated with the ex

84 Myotonic dystrophy (DM)--the most common form of muscula

85 is a key player in the disease mechanism of myotonic dystrophy (DM).

86 tal muscle development and are implicated in myotonic dystrophy (DM).

87 pathogenic event in the RNA-mediated disease myotonic dystrophy (DM).

88 PURPOSE OF REVIEW: The myotonic dystrophies (DM1 and DM2) are the paradigm for

89 UGn RNA in the induction of stress in type 1 myotonic dystrophy (DM1) cells and in the stress-mediate

90 Myotonic dystrophy (DM1) is a highly variable, multi-sys

91 Myotonic dystrophy (DM1) is an autosomal dominant neurom

92 Type I myotonic dystrophy (DM1) is caused by a triplet repeat e

93 Myotonic dystrophy (DM1) is caused by an expansion of CU

94 Myotonic dystrophy (DM1) is the most common form of adul

95 In myotonic dystrophy (DM1), both inactivation of musclebli

96 Myotonic dystrophy (DM1), the most common muscular dystr

97 ein implicated in the pathogenesis of type I myotonic dystrophy (DM1).

98 ated with the degenerative muscular disease, myotonic dystrophy (DM1).

99 ated with expanded repeat sequences, such as myotonic dystrophy (DM1).

100 The genetic lesion in myotonic dystrophy does not eliminate an essential muscl

101 In myotonic dystrophy (dystrophia myotonica [DM]), an incre

102 s of European origin with PROMM and proximal myotonic dystrophy, from geographically distinct populat

103 ated with multiple human diseases, including myotonic dystrophy, Fuchs endothelial corneal dystrophy,

104 hanism of cardiac and muscle degeneration in myotonic dystrophy has been re-evaluated through a serie

105 Research on myotonic dystrophy has led to the recognition of a novel

106 Many neurological diseases, including myotonic dystrophy, Huntington's disease and several spi

107 AA)n, are associated with diseases including myotonic dystrophy, Huntington's disease, fragile X and

108 unction is a prominent cause of mortality in myotonic dystrophy I (DM1), a disease where expanded CUG

109 in the development of RNA splice defects in myotonic dystrophy I (DM1), we purified RNA-independent

110 s also responsible for the manifestations of myotonic dystrophy in non-muscle tissues.

111 r phenotype reflects many of the features of myotonic dystrophy, including muscle histological morpho

112 3' UTR mRNA reproduced cardinal features of myotonic dystrophy, including myotonia, cardiac conducti

113 The pathomechanism for the myotonic dystrophies is not well understood and the role

114 Myotonic dystrophy is a complex neuromuscular disorder a

115 Therapeutic development for myotonic dystrophy is moving rapidly with the developmen

116 RECENT FINDINGS: RNA toxicity in myotonic dystrophy is now associated with bi-directional

117 It now appears likely that myotonic dystrophy is the first instance of a genetic di

118 In myotonic dystrophy it is the RNA rather than protein pro

119 In the best studied example, myotonic dystrophy, it appears that the main pathogenic

120 roteins HSP20, HSP25, alphaB-crystallin, and myotonic dystrophy kinase binding protein (MKBP) may reg

121 MRCK (myotonic dystrophy kinase-related Cdc42 binding kinase),

122 Myotonic dystrophy kinase-related Cdc42-binding kinase (

123 ation and invasion by binding and activating myotonic dystrophy kinase-related CDC42-binding kinase a

124 Caspase-mediated cleavage of myotonic dystrophy kinase-related CDC42-binding kinase-a

125 ls have been implicated in schizophrenia and myotonic dystrophy (MD), and both conditions carry an in

126 phasis on key updates in muscular dystrophy, myotonic dystrophy, mitochondrial myopathy, spinal muscu

127 hronic progressive external ophthalmoplegia, myotonic dystrophy, neurofibromatosis type 2, and basal

128 an skeletal actin (HSA)(LR) mice (a model of myotonic dystrophy) of various ages.

129 cell culture model of myotonic dystrophy and myotonic dystrophy patient tissue, we have evidence that

130 L1, a splicing factor that is sequestered in myotonic dystrophy patients by binding to expanded r(CUG

131 In human cells from myotonic dystrophy patients, treatment with 5-aza-CdR st

132 e variant CaV1.1e in the skeletal muscles of myotonic dystrophy patients.

133 sed Znf9 and Clc1 expression and rescued the myotonic dystrophy phenotype in Znf9+/- mice.

134 e Znf9 haploinsufficiency contributes to the myotonic dystrophy phenotype in Znf9+/- mice.

135 e whether SIX5 deficiency contributes to the myotonic dystrophy phenotype, we disrupted mouse Six5 by

136 e basis for a new type of instability of the myotonic dystrophy protein kinase (DMPK) gene in patient

137 Human myotonic dystrophy protein kinase (DMPK) is a member of

138 Myotonic dystrophy protein kinase (DMPK), a muscle- and

139 G)n tract in the 3' UTR of the gene encoding myotonic dystrophy protein kinase (DMPK), which results

140 ' untranslated region of the gene coding for myotonic dystrophy protein kinase (DMPK).

141 Abnormal expression of human myotonic dystrophy protein kinase (hDMPK) gene products

142 let-repeat expansion region from a truncated myotonic dystrophy protein kinase transcript mimic in vi

143 -coil domain reminiscent of eukaryotic DMPK (Myotonic Dystrophy Protein Kinase) family kinases such a

144 In mammalian cells, the myotonic dystrophy-related Cdc42-binding kinase possesse

145 By this mechanism, effects of myotonic dystrophy repeat expansions impact many differe

146 ct phenotype in myotonic dystrophy, and that myotonic dystrophy represents a multigenic disorder.

147 d the pathobiology of disease mechanisms for myotonic dystrophy, spinal muscular atrophy, and fragile

148 ersion is the likely expansion mechanism for myotonic dystrophy, spinocerebellar ataxia type 8, and f

149 ar ataxia, amyotrophic lateral sclerosis and myotonic dystrophy) that involve mutations within the an

150 In both types of myotonic dystrophy the expanded repeat is transcribed an

151 c mechanisms that have been proposed for the myotonic dystrophies, the clinical and molecular feature

152 In myotonic dystrophy, the expression of expanded CUG repea

153 In myotonic dystrophy, the lack of properly localized MBNL1

154 rnative splicing and have been implicated in myotonic dystrophy, the most common form of adult onset

155 ansions of noncoding CUG and CCUG repeats in myotonic dystrophies type 1 (DM1) and DM2 cause complex

156 Myotonic dystrophies type 1 (DM1) and type 2 (DM2) are n

157 Myotonic dystrophies type 1 and type 2 are progressive m

158 tive approach to screening and management of myotonic dystrophies type 1 and type 2 requires a multid

159 human samples from patients with congenital myotonic dystrophy type 1 (CDM1) and spinal muscular atr

160 with Huntington's disease (CAG repeats) and myotonic dystrophy type 1 (CTG repeats).

161 anded rCUG and rCAG repeat RNAs expressed in myotonic dystrophy type 1 (DM1) and spinocerebellar atax

162 Myotonic dystrophy type 1 (DM1) and type 2 (DM2) are cau

163 d CCUG are the underlying genetic causes for myotonic dystrophy type 1 (DM1) and type 2 (DM2), respec

164 sequence is considered a causative agent of myotonic dystrophy type 1 (DM1) because of its ability t

165 nscript (CUG(exp)) is the causative agent of myotonic dystrophy type 1 (DM1) by sequestering musclebl

166 man spinocerebellar ataxia type 8 (SCA8) and myotonic dystrophy type 1 (DM1) CAG expansion transcript

167 disease (HD) FEN1 +/- heterozygous mice and myotonic dystrophy type 1 (DM1) FEN1 +/- heterozygous mi

168 A working hypothesis for the pathogenesis of myotonic dystrophy type 1 (DM1) involves the aberrant se

169 Myotonic dystrophy type 1 (DM1) is a complex neuromuscul

170 The genetic basis of myotonic dystrophy type 1 (DM1) is a CTG expansion in th

171 Myotonic dystrophy type 1 (DM1) is a CTG microsatellite

172 Myotonic dystrophy type 1 (DM1) is a dominant neuromuscu

173 Myotonic Dystrophy type 1 (DM1) is a dominant neuromuscu

174 Myotonic dystrophy type 1 (DM1) is a dominantly inherite

175 Myotonic dystrophy type 1 (DM1) is a genetic disorder in

176 Myotonic dystrophy type 1 (DM1) is a genetic disorder li

177 Myotonic dystrophy type 1 (DM1) is a microsatellite expa

178 Myotonic dystrophy type 1 (DM1) is a neuromuscular disor

179 Myotonic dystrophy Type 1 (DM1) is a rare genetic diseas

180 Myotonic dystrophy type 1 (DM1) is a triplet repeating d

181 Myotonic dystrophy type 1 (DM1) is an autosomal dominant

182 Myotonic dystrophy type 1 (DM1) is an autosomal dominant

183 Myotonic dystrophy type 1 (DM1) is an inherited dominant

184 Myotonic dystrophy type 1 (DM1) is an RNA dominant disea

185 Myotonic dystrophy type 1 (DM1) is an RNA-dominant disea

186 Myotonic dystrophy type 1 (DM1) is associated with expan

187 Myotonic dystrophy type 1 (DM1) is caused by a CTG expan

188 Myotonic dystrophy type 1 (DM1) is caused by a CTG expan

189 Myotonic dystrophy type 1 (DM1) is caused by a CTG trinu

190 Myotonic dystrophy type 1 (DM1) is caused by a CTG trinu

191 Myotonic dystrophy type 1 (DM1) is caused by a CUGn expa

192 Myotonic dystrophy type 1 (DM1) is caused by expansion o

193 Myotonic dystrophy type 1 (DM1) is caused by expansion o

194 Myotonic dystrophy type 1 (DM1) is caused by the expansi

195 Myotonic dystrophy type 1 (DM1) is one of a growing numb

196 Myotonic dystrophy type 1 (DM1) is one of the most varia

197 Myotonic dystrophy type 1 (DM1) is one such disorder tha

198 Myotonic dystrophy type 1 (DM1) is the most common form

199 ion hypothesis for the CTG expansion causing myotonic dystrophy type 1 (DM1) located in the 3' noncod

200 The disease mechanism underlying myotonic dystrophy type 1 (DM1) pathogenesis in skeletal

201 Accumulation of RNA CUG repeats in myotonic dystrophy type 1 (DM1) patients leads to the in

202 In myotonic dystrophy type 1 (DM1), an expanded CTG repeat

203 In myotonic dystrophy type 1 (DM1), dystrophia myotonica pr

204 splicing has become a molecular hallmark of myotonic dystrophy type 1 (DM1), in which neonatal splic

205 ough cataract is a characteristic feature of myotonic dystrophy type 1 (DM1), little is known of the

206 and GAA.TTC are integral to the etiology of myotonic dystrophy type 1 (DM1), myotonic dystrophy type

207 Myotonic dystrophy type 1 (DM1), the most common form of

208 Myotonic dystrophy type 1 (DM1), the most common form of

209 Myotonic dystrophy type 1 (DM1), the most common muscula

210 Myotonic dystrophy type 1 (DM1), the most prevalent musc

211 In the hereditary degenerative disease myotonic dystrophy type 1 (DM1), transcripts from the mu

212 In myotonic dystrophy type 1 (DM1), triplet repeat expansio

213 date disease for RNAi therapy application is myotonic dystrophy type 1 (DM1), which results from toxi

214 (hDMPK) gene products has been implicated in myotonic dystrophy type 1 (DM1), yet the impact of distr

215 S; trisomy 21) and the dementia component of myotonic dystrophy type 1 (DM1).

216 als with the inherited multisystemic disease myotonic dystrophy type 1 (DM1).

217 ting symptom experienced by individuals with myotonic dystrophy type 1 (DM1).

218 d pathogenic role of expanded CUG repeats in myotonic dystrophy type 1 (DM1).

219 ocess is impaired in patients afflicted with myotonic dystrophy type 1 (DM1).

220 rationally designed, multi-target agents for myotonic dystrophy type 1 (DM1).

221 h are disrupted on loss of MBNL1 function in myotonic dystrophy type 1 (DM1).

222 rophia myotonica protein kinase (DMPK) cause myotonic dystrophy type 1 (DM1).

223 METHODS AND We selected 855 patients with myotonic dystrophy type 1 (women, 51%; median age, 37 ye

224 cause dominantly inherited diseases such as myotonic dystrophy type 1 and 2 (DM1/2), Huntington's di

225 Friedreich ataxia, myotonic dystrophy type 1 and 3 forms of intellectual di

226 detected in mouse models with DCM, including myotonic dystrophy type 1 and CELF1 overexpression model

227 s previously characterized in the context of myotonic dystrophy type 1 and epithelial-to-mesenchymal

228 se sequences are involved in the etiology of myotonic dystrophy type 1 and Friedreich's ataxia, respe

229 Myotonic dystrophy type 1 and type 2 (DM1 and DM2) are g

230 ress in elucidating the disease mechanism in myotonic dystrophy type 1 and type 2.

231 Patients with adult myotonic dystrophy type 1 are at high risk for arrhythmi

232 ng in the molecular and clinical features of myotonic dystrophy type 1 as well as the screening of cl

233 epeats (CUG(exp)) are the causative agent of myotonic dystrophy type 1 by sequestering MBNL1.

234 Up to one-third of patients with myotonic dystrophy type 1 die suddenly.

235 Historically, patients with myotonic dystrophy type 1 have not received the medical

236 Myotonic dystrophy type 1 is an autosomal dominant disor

237 Myotonic dystrophy type 1 is caused by the dysregulation

238 Previous studies have shown that myotonic dystrophy type 1 is caused by the expansion of

239 The average age of death in myotonic dystrophy type 1 is in the fifth decade.

240 Myotonic dystrophy type 1 is the most prevalent muscular

241 he size of the CTG expansion in the blood of myotonic dystrophy type 1 patients is associated with to

242 n contrast to the CUG-RNA hairpins formed by myotonic dystrophy type 1 repeats, we found no evidence

243 der than 18 years with genetically confirmed myotonic dystrophy type 1 who were admitted to the Neuro

244 How this untranslated CTG expansion causes myotonic dystrophy type 1(DM1) has been controversial.

245 Among patients with myotonic dystrophy type 1, an invasive strategy was asso

246 nine had myotonic dystrophy type 2, one had myotonic dystrophy type 1, and 17 had no identified muta

247 ples from individuals with one such disease, myotonic dystrophy type 1, provides an opportunity to pa

248 f Friedreich ataxia, fragile X syndrome, and myotonic dystrophy type 1, respectively.

249 dementia, fragile X tremor ataxia syndrome, myotonic dystrophy type 1, spinocerebellar ataxia type 8

250 In myotonic dystrophy type 1, the association between mutat

251 Similar to myotonic dystrophy type 1, the poly(CUG)n RNA co-localiz

252 atrophy, amyotrophic lateral sclerosis, and myotonic dystrophy type 1, were also reviewed.

253 Exon 2 is significantly reduced in myotonic dystrophy type 1, whose symptoms include dement

254 uation, out of 1014 patients included in the Myotonic Dystrophy Type 1-Heart Registry between January

255 ive diseases, such as Huntington disease and myotonic dystrophy type 1.

256 tracts in the size range that is typical for myotonic dystrophy type 1.

257 n abnormalities in the neuromuscular disease myotonic dystrophy type 1.

258 06 adult patients with genetically confirmed myotonic dystrophy type 1.

259 atrophy, amyotrophic lateral sclerosis, and myotonic dystrophy type 1.

260 xpansions observed in human diseases such as myotonic dystrophy type 1.

261 atrophy, amyotrophic lateral sclerosis, and myotonic dystrophy type 1.

262 disorders, including Huntington disease and myotonic dystrophy type 1.

263 en implicated in the cardiac pathogenesis of myotonic dystrophy type 1.

264 er onset of symptoms and is less common than myotonic dystrophy type 1.

265 myotonica protein kinase (DMPK) gene causes myotonic dystrophy type 1.

266 able therapeutic target for the treatment of myotonic dystrophy type 1.

267 ranslated CCTG expansion in an intron causes myotonic dystrophy type 2 (DM2) have uncovered a new typ

268 Myotonic dystrophy type 2 (DM2) is a genetic disorder ch

269 Myotonic dystrophy type 2 (DM2) is a multisystemic disor

270 Myotonic dystrophy type 2 (DM2) is an incurable neuromus

271 Myotonic dystrophy type 2 (DM2) is caused by a CCTG expa

272 The recent discovery that myotonic dystrophy type 2 (DM2) is caused by an untransl

273 Myotonic dystrophy type 2 (DM2) is caused by the extreme

274 ponsible for the massive expansions found in myotonic dystrophy type 2 (DM2) patients.

275 At some sites of repeat expansion, e.g. the myotonic dystrophy type 2 (DM2) tetranucleotide repeat e

276 ribed but untranslated CCTG expansion causes myotonic dystrophy type 2 (DM2), along with other discov

277 oops in r(CCUG)(exp), the causative agent of myotonic dystrophy type 2 (DM2), and are transformed int

278 etiology of myotonic dystrophy type 1 (DM1), myotonic dystrophy type 2 (DM2), and Friedreich's ataxia

279 Recently, it was discovered that myotonic dystrophy type 2 (proximal myotonic myopathy) i

280 ofilm formation in Staphylococcus aureus and myotonic dystrophy type 2 in human, respectively.

281 Myotonic dystrophy type 2 is a genetic neuromuscular dis

282 Myotonic dystrophy type 2 is caused by a (CCTG)/(CCUG)n

283 not well understood and the role of ZNF9 in myotonic dystrophy type 2 pathogenesis has not been full

284 In comparison, myotonic dystrophy type 2 tends to cause a milder phenot

285 We explored this question using myotonic dystrophy type 2, a multisystemic disease thoug

286 irst intron of the ZNF9 gene associated with myotonic dystrophy type 2, form slipped-strand DNA struc

287 s, 34 had sodium channel mutations, nine had myotonic dystrophy type 2, one had myotonic dystrophy ty

288 l mutations, chloride channel mutations, and myotonic dystrophy type 2.

289 The neuromuscular disease myotonic dystrophy type I (DM1) affects multiple organ s

290 Myotonic dystrophy type I (DM1) exhibits distinctive dis

291 Myotonic dystrophy type I (DM1) is a disabling multisyst

292 Myotonic dystrophy type I (DM1) is a disabling neuromusc

293 Myotonic dystrophy type I (DM1) is an RNA-mediated disea

294 They contain CUG repeats, relevant to myotonic dystrophy type I, and CAG repeats associated wi

295 The phenotypes in myotonic dystrophy types 1 and 2 (DM1 and DM2) are simil

296 muscleblind function and the pathogenesis of myotonic dystrophy, we generated Drosophila incorporatin

297 eases, including spinal muscular atrophy and myotonic dystrophy, where defects of splicing or alterna

298 operties of potential therapeutic agents for myotonic dystrophy, which is caused by sequestration of

299 Molecular therapeutics for myotonic dystrophy will probably bridge the translationa

300 ment for clinical screening of patients with myotonic dystrophy with proactive and systematic managem